Prenatal benign hypophosphatasia

Prenatal benign hypophosphatasia is a rare, mild form of hypophosphatasia (HPP) that is detected before birth through prenatal ultrasound imaging. Hypophosphatasia is caused by deficiency of tissue-nonspecific alkaline phosphatase (TNSALP), encoded by the ALPL gene. In this benign prenatal form, skeletal abnormalities such as bowing of the long bones and reduced mineralization are observed on fetal ultrasound, raising concern for a more severe perinatal form of hypophosphatasia. However, the skeletal findings spontaneously improve during the third trimester of pregnancy or in the postnatal period, and the clinical outcome is generally favorable. The condition primarily affects the skeletal system. Key prenatal features include limb shortening and bowing of the femora and other long bones, which may mimic the appearance of severe skeletal dysplasias. Importantly, these findings resolve or significantly improve over time, distinguishing this form from the lethal perinatal and severe infantile forms of hypophosphatasia. Biochemically, affected individuals may show low serum alkaline phosphatase levels. The prognosis is generally good, and most affected children develop normally or have only mild residual skeletal manifestations. Because of its benign course, prenatal benign hypophosphatasia typically does not require specific treatment. Accurate diagnosis is critical to avoid unnecessary interventions or pregnancy termination based on the initial alarming ultrasound findings. Genetic counseling and molecular testing of the ALPL gene can help confirm the diagnosis and distinguish this form from more severe subtypes. Enzyme replacement therapy with asfotase alfa, which is available for severe forms of hypophosphatasia, is generally not indicated in this benign variant.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Prenatal benign hypophosphatasia